Close Menu

Not This Time

The first human stem-cell based drug failed two late-stage clinical trials, reports the New York Times. The drug, Prochymal, from Osiris Therapeutics was made from mesenchymal stem cells from healthy young adults and was found to be no more effective than placebo in treating graft-versus-host disease. Prochymal did, however, appear to have an effect in a subset of patients. "Prochymal is having a clear effect in the liver, and that is the most underserved patient population," CEO C.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.